Reports Q1 revenue $515.3M, consensus $511.97M. “Significant unmet need still exists for the many patients living with tardive dyskinesia as exemplified with INGREZZA’s first quarter year-over-year growth of 23%,” said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “With the recent New Drug Application submissions for crinecerfont, positive Phase 2 results for a potential first-in-class medication in NBI-‘845 for major depressive disorder, and the deepest pipeline in our company’s history, Neurocrine Biosciences is well positioned to become a leader in neuroscience.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- NBIX Upcoming Earnings Report: What to Expect?
- Tesla, Airbnb upgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
- Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo